Related Experiment Video
Updated: May 20, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells
Dong-Dong Cheng1, Qing-Cheng Yang, Zhi-Chang Zhang
1Department of Orthopeadics, Sixth People's Hospital, Shanghai JiaoTong University, Shanghai, China.
Background:
Histone deacetylase (HDAC) inhibitors have been reported to induce cell growth arrest, apoptosis and differentiation of tumor cells. The present study aimed to examine the effects of trichostatin A (TSA), one such inhibitor, on the cell cycle, apoptosis and invasiveness of osteosarcoma cells.
Methods:
MG- 63 cells were treated with TSA at various concentrations. Then, cell growth and apoptosis were determined by 3-(4, 5-dimethyl-2-thiazolyl)-2H-tetrazolium bromide (MTT) and TUNEL assays, respectively; cell cycling was assessed by flow cytometry; invasion assays were performed with the transwell Boyden Chamber system.
Results:
MTT assays revealed that TSA significantly inhibited the growth of MG-63 cells in a concentration and time dependent manner. TSA treated cells demonstrated morphological changes indicative of apoptosis and TUNEL assays revealed increased apoptosis of MG-63 cells after TSA treatment. Flow cytometry showed that TSA arrested the cell cycle in G1/G2 phase and annexin V positive apoptotic cells increased markedly. In addition, the invasiveness of MG-63 cells was inhibited by TSA in a concentration dependent manner.
Conclusion:
Our findings demonstrate that TSA inhibits the proliferation, induces apoptosis and inhibits invasiveness of osteosarcoma cells in vitro. HDAC inhibitors may thus have promise to become new therapeutic agents against osteosarcoma.
Insights
Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, significantly reduces osteosarcoma cell growth and invasion. TSA also effectively induces apoptosis, suggesting its potential as a novel therapeutic agent for osteosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Histone deacetylase (HDAC) inhibitors show promise in cancer therapy by affecting tumor cell growth, apoptosis, and differentiation.
- Osteosarcoma is a primary malignant bone tumor with significant metastatic potential.
Purpose of the Study:
- To investigate the effects of trichostatin A (TSA), an HDAC inhibitor, on the cell cycle, apoptosis, and invasiveness of osteosarcoma cells.
- To evaluate the therapeutic potential of TSA in osteosarcoma treatment.
Main Methods:
- MG-63 osteosarcoma cells were treated with varying concentrations of TSA.
- Cell proliferation was assessed using MTT assays.
- Apoptosis was evaluated via TUNEL assays and Annexin V staining.
- Cell cycle progression was analyzed by flow cytometry.
- Invasiveness was measured using transwell Boyden Chamber assays.
Main Results:
- TSA significantly inhibited MG-63 cell proliferation in a dose- and time-dependent manner.
- TSA treatment led to increased apoptosis and cell cycle arrest in the G1/G2 phase.
- The invasiveness of osteosarcoma cells was markedly reduced by TSA in a concentration-dependent manner.
Conclusions:
- Trichostatin A effectively inhibits proliferation, induces apoptosis, and reduces invasiveness of osteosarcoma cells in vitro.
- HDAC inhibitors like TSA represent a promising therapeutic strategy for osteosarcoma.
- Further research into TSA as a potential anti-osteosarcoma agent is warranted.
